Effect of BCG in treatment of diabetes type 1

Evaluation the effect of two doses of BCG vaccine on inflammatory factors in the glycemic control on type 1 diabetic patients, a quasi-experimental clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201012049003N1

Enrollment

Registered

2020-10-15

Start date

2020-10-16

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes type1. Type 1 diabetes mellitus with ketoacidosis

Interventions

Intervention group: Diabetes type1 patients, BCG vaccine, two injections at one month intervals.

Eligibility

Sex/Gender

All

Age

6 Years to 14 Years

Inclusion criteria

Inclusion criteria: HbA1C>7 Get the full dose of insulin having diabetes for at least 1 year (to pass the Honeymoon course) Age category 6 to 14 years

Exclusion criteria

Exclusion criteria: retinopathy Nephropathy Diabetic neuropathy Macrovascular complications of diabetes HbA1C<7 New cases of type 1 diabetes Having a recurrent infection or a history of allergy to the vaccine at birth Take high doses of corticosteroids History of immunodeficiency disease celiac

Design outcomes

Primary

Measure	Time frame
HbA1c level in patients. Timepoint: Measurement of HbA1c at the beginning of the study and 3, 6, 9, and 12 months after the first vaccine was given. Method of measurement: blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahtab Ordooie

Yazd University of Medical Sciences

dr.ordooei@yahoo.com+98 35 3728 0226

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026